[1] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
[2] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|
[3] |
LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa.
Relevance of CYP2R1 genetic polymorphism and individual therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
|
[4] |
CHEN Yan, ZHU Lijun, FANG Zhengmei, ZHU Hui, JIN Yuelong, SHEN Chong, YAO Yingshui.
Association of insulin-like growth factor(IGF)-1 polymorphisms and efficacy of antihypertensive drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 171-179.
|
[5] |
CHEN Binyao, LI Ling, ZHAO Huijia, LIU Xiaohong, QI Zhenhua, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, DONG Li, YUE Jiang, YE Qifa.
Relevance of CYP1B1 genetic polymorphism and individual therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1309-1316.
|
[6] |
ZHOU Yuan, LU Xueling, ZHAO Jun, ZHANG Li, YANG Huanjie,WANG Ning.
Polymorphism distribution of rs316019 of SLC22A2 in the Uygur population of Xinjiang
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 287-293.
|
[7] |
LIN Xiuxian, CHEN Dan, ZHAO Qing, CHEN Yao.
Genetic research on the incidence of alcoholic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1309-1314.
|
[8] |
HU Jing, ZHU Jun-rong, YU Feng.
Efficacy and safety of warfarin dosage algorithms in clinical application:A Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 296-303.
|
[9] |
MA Xiao-qin, XIN Hua-wen, LI Yuan-qi, HUANG Hui, ZHAO Li, YU Ai-rong, LI Wei-liang, WU Xiao-chun.
Association of HGPRT activity and gene polymorphism with adverse reactions caused by azathioprine in kidney transplant recipients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 182-187.
|
[10] |
WU Ji-chu, OUYANG Ze-wei, LUO Can-xiang.
Effect of ABCG2 genetic polymorphism on atorvastatin modifying serum lipids
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 882-884.
|
[11] |
OUYANG Cang-hong, XIE Juan.
Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.
|
[12] |
FENG Jing, WU Yue, RONG Pei-pei, SHEN Bing-zheng, ZHOU Ding-shan, SHI Cai, SONG Jin-chun.
Progress on effects of pharmacogenetics of inosine triphosphate pyrophosphatase on improving the individualized thiopurine therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1435-1440.
|
[13] |
HUANG Lu, YANG Guo-ping.
Progress on influence of cytochrome P450 oxidoreductase polymorphisms on cytochrome P450 monoxyfenases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 818-823.
|
[14] |
NING Wei, LIU Jie.
Research advances in pharmacogenomics of levodopa
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 455-460.
|
[15] |
HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei.
Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.
|